Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Platinum-resistant Recurrent Ovarian Cancer Clinical Trial

Official title:

Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer: a Prospective, Single-arm, Open Label, Exploratory Phase 2 Clinical Trial.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04720807
• Other study ID #: XH-21-001
• Status: Recruiting
• Phase: Phase 2
• Start date: September 1, 2020
• Est. completion date: September 30, 2023

Study information

• Verified date: January 2021
• Source: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• Contact: Xipeng Wang, Doctor
• Phone: 86-021-25078999
• Email: wangxipeng[@]xinhuamed.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum-resistant recurrent ovarian cancer.

Description:

The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum-resistant recurrent ovarian cancer.The patient has undergone surgery and received ≥2 lines of platinum-containing chemotherapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: September 30, 2023
• Est. primary completion date: August 31, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. 18 years of age or older;

2. Eastern Cooperative Oncology Group (ECOG) performance status = 2;

3. Histologically diagnosed epithelial ovarian cancer (high-grade serous, clear cell, endometrioid ovarian cancer), fallopian tube cancer or primary peritoneal cancer;

4. The patient has undergone surgery and received =2 lines of platinum-containing chemotherapy. During the treatment period of the platinum-containing regimen (from the beginning of the treatment to 1 month after the last chemotherapy), the curative effect is non-PD, and the disease relapse/progress within 6 months after the treatment;

5. The patient has measurable lesions with imaging evidence;

6. The expected survival period = 3 months;

7. Estrogen receptor (ER) is positive in immunohistochemistry of the first or the last surgical specimens;

8. Adequate organ function at screening:

1) Adequate bone marrow function at screening: Hemoglobin =90 g/L (no blood transfusion within 14 days); Neutrophil =1.5×109/L; Platelets =80×109/L; 2) Biochemical test: Total bilirubin=1.5×ULN (upper limit of normal); Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 2.5×ULN; if there is liver metastasis, ALT or AST = 5×ULN; Serum creatinine = 1.5×ULN or endogenous creatinine clearance = 50ml/min (Cockcroft-Gault formula); 9. The patient has not been treated with other tyrosine kinase inhibitor (TKI) drugs; 10. The patient has not received tumor endocrine therapy; 11. Patients should have good compliance and the family members agree to cooperate in the survival follow-up.

Exclusion Criteria:

1. Patients with other malignant tumors at the same time except for recovery or tumors in a stable state.

2. Pregnant or breast feeding women;

3. Patients participated in other drug clinical trials within six months;

4. Patients with many factors that affect oral drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.);

5. Any bleeding event with a severity level of grade = 3 in CTCAE 4.0 in the 4 weeks before screening;

6. Patients with known central nervous system metastasis or a history of the metastasis before screening;

7. Patients with hypertension who cannot be well controlled by antihypertensive drugs (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg); those with a history of unstable angina; those who are newly diagnosed with angina within 3 months before screening or Myocardial infarction occurred within 6 months before screening; arrhythmia requires long-term use of antiarrhythmic drugs and New York Heart Association grade = II cardiac insufficiency;

8. Long-term unhealed wounds or incomplete fractures;

9. A previous history of organ transplantation;

10. Imaging shows that the tumor has invaded important blood vessels or the researcher has judged that the patient's tumor is highly likely to invade important blood vessels to induce fatal bleeding during treatment;

11. Abnormal coagulation function (PT>16s, APTT>43s, TT>21s, Fbg<2g/L); those with bleeding tendency (INR is normal without using anticoagulants in 14 days before randomization); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or their analogs; under the condition of INR = 1.5, Low-dose warfarin (1 mg orally, once a day) or low-dose aspirin (do not exceed 100 mg per day) is permitted for preventive purposes;

12. Arteriovenous thrombosis events occurred within one year before screening, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis (venous thrombosis caused by intravenous catheterization due to pre-chemotherapy, except those who have been cured), and pulmonary embolism;

13. Those who have a history of psychotropic drug abuse and can't be prevented or have mental disorders;

14. Have a history of immunodeficiency, or have a history of organ transplantation;

15. According to the judgment of the investigator, there are accompanying diseases that seriously endanger the safety of the patient or affect the completion of the study;

16. Have a history of surgery within 28 days;

17. A history of abdominal fistula or gastrointestinal perforation within 28 days;

18. People who may receive other systemic anti-tumor treatments or plan to undergo ovarian cancer reduction surgery during the study period.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Ovarian Neoplasms
• Platinum-resistant Recurrent Ovarian Cancer

Intervention

Drug:
• Letrozole combined with anlotinib hydrochloride
Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.

Locations

Country	Name	City	State
China	Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR	objective response rate	3 years
Secondary	PFS	progression-free survival time	3 years and 5 years
Secondary	OS	Overall survival	3 years and 5 years
Secondary	AE	Adverse event	3 years and 5 years